Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566904 · ClinicalTrials.gov registry record · Phase 1
New Topical Treatment for Continued Pain After Shingles
A Phase 1 study, sponsored by Biomedical Development Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00566904 is a Phase 1 study that has completed, run by Biomedical Development Corporation. The registered enrollment target is 30 participants.
The verdict
NCT00566904, a Phase 1 study, has completed, sponsored by Biomedical Development Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as postherpetic neuralgia. The purpose of this study is to evaluate the effectiveness of a new topical treatment for postherpetic neuralgia in adults.
Interventions
- DRUG Epikeia coatings with aspirin
- DRUG Epikeia coatings with lidocaine
- OTHER Epikeia coatings alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566904
The ClinicalTrials.gov registry entry for NCT00566904 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomedical Development Corporation, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Epikeia coatings with aspirin is the first listed.
NCT00566904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00566904 about?
NCT00566904 is a clinical study titled "New Topical Treatment for Continued Pain After Shingles". Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as postherpetic neuralgia. The purpose of this study is to evaluate the ef...
What is the current status of trial NCT00566904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00566904?
The interventions under investigation include: Epikeia coatings with aspirin (DRUG), Epikeia coatings with lidocaine (DRUG), Epikeia coatings alone (OTHER).
Who is sponsoring clinical trial NCT00566904?
This trial is sponsored by Biomedical Development Corporation, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.